Lumexa Posts Q3 Results, Reaffirms 8-10 New Centers for 2026
LMRI has more than doubled off its 52-week low of $6.45.
Summary
Lumexa released Q3 2026 results and an updated full-year outlook, but the release text circulating carries no revenue, margin, or guidance figures, so the direction of any change can't be judged from this alone. The 8-K filed at 21:05 ET the same evening does contain numbers: net income of $7.2 million versus a $3.5 million loss a year ago, and Adjusted EBITDA of $62.6 million. That extends the turnaround shown in Q2, when the company first swung to net profit on lower interest expense from its debt refinancing. Management also said it remains on pace for 8-10 new center openings in 2026, which is capacity growth rather than a near-term revenue number. The key open item is the actual guidance range in the full release — without it, the quarter reads as steady execution rather than a re-rating event.
At the time of this announcement, LMRI was trading at $13.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $6.45 to $19.45. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.